IO Biotech (NASDAQ:IOBT) vs. Anebulo Pharmaceuticals (NASDAQ:ANEB) Head-To-Head Contrast

IO Biotech (NASDAQ:IOBT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Earnings & Valuation

This table compares IO Biotech and Anebulo Pharmaceuticals’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08 million	($1.87)	-0.60
Anebulo Pharmaceuticals	N/A	N/A	-$11.73 million	($0.37)	-6.49

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IO Biotech and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-69.31%	-62.21%
Anebulo Pharmaceuticals	N/A	-122.98%	-109.29%

Volatility & Risk

IO Biotech has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IO Biotech and Anebulo Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0	0	3	0	3.00
Anebulo Pharmaceuticals	0	0	3	0	3.00

IO Biotech currently has a consensus price target of $9.67, suggesting a potential upside of 755.46%. Anebulo Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 177.78%. Given IO Biotech’s higher possible upside, research analysts plainly believe IO Biotech is more favorable than Anebulo Pharmaceuticals.

Institutional and Insider Ownership

54.8% of IO Biotech shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 2.3% of IO Biotech shares are held by company insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

IO Biotech beats Anebulo Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About IO Biotech

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.